KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $26.29 Consensus PT from Analysts

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine analysts that are currently covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $26.2857.

A number of analysts have recently weighed in on the stock. JMP Securities raised their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a report on Tuesday, July 8th. Leerink Partners raised their price target on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a report on Monday, July 7th. Finally, HC Wainwright increased their price objective on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 32,979 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total transaction of $517,440.51. Following the completion of the transaction, the chief executive officer directly owned 369,595 shares of the company's stock, valued at $5,798,945.55. The trade was a 8.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN lifted its position in shares of KalVista Pharmaceuticals by 29.1% during the fourth quarter. Wells Fargo & Company MN now owns 20,165 shares of the specialty pharmaceutical company's stock worth $171,000 after purchasing an additional 4,543 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of KalVista Pharmaceuticals by 15.2% in the fourth quarter. Russell Investments Group Ltd. now owns 133,572 shares of the specialty pharmaceutical company's stock valued at $1,131,000 after acquiring an additional 17,580 shares during the period. Legal & General Group Plc boosted its holdings in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after acquiring an additional 1,494 shares during the period. XTX Topco Ltd acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at approximately $267,000. Finally, Marshall Wace LLP grew its position in KalVista Pharmaceuticals by 691.5% in the 4th quarter. Marshall Wace LLP now owns 117,978 shares of the specialty pharmaceutical company's stock valued at $999,000 after buying an additional 103,072 shares during the last quarter.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock traded up $0.45 during midday trading on Tuesday, hitting $13.41. 590,122 shares of the company's stock were exchanged, compared to its average volume of 796,626. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $16.32. The firm has a 50-day moving average of $13.40 and a two-hundred day moving average of $12.34. The company has a market cap of $669.83 million, a PE ratio of -3.63 and a beta of 0.05.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same quarter last year, the company posted ($1.07) EPS. As a group, equities analysts expect that KalVista Pharmaceuticals will post -3.56 earnings per share for the current year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).